Goldman Sachs’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-913,245
| Closed | -$68.7M | – | 6824 |
|
|
2022
Q2 | $68.7M | Buy |
913,245
+68,784
| +8% | +$3.06M | 0.02% | 906 |
|
|
2022
Q1 | $22.7M | Buy |
844,461
+43,252
| +5% | +$1.45M | ﹤0.01% | 1956 |
|
|
2021
Q4 | $38.2M | Buy |
801,209
+80,946
| +11% | +$3.62M | 0.01% | 1562 |
|
|
2021
Q3 | $47.8M | Sell |
720,263
-5,841
| -0.8% | -$416K | 0.01% | 1322 |
|
|
2021
Q2 | $56.6M | Buy |
726,104
+315,322
| +77% | +$23.3M | 0.01% | 1143 |
|
|
2021
Q1 | $38.9M | Sell |
410,782
-117,427
| -22% | -$14M | 0.01% | 1375 |
|
|
2020
Q4 | $64.4M | Buy |
528,209
+86,936
| +20% | +$9.52M | 0.02% | 919 |
|
|
2020
Q3 | $38.5M | Buy |
441,273
+35,418
| +9% | +$2.47M | 0.01% | 1196 |
|
|
2020
Q2 | $26.2M | Buy |
405,855
+210,821
| +108% | +$12.2M | 0.01% | 1459 |
|
|
2020
Q1 | $8.71M | Buy |
195,034
+80,244
| +70% | +$4.26M | ﹤0.01% | 2186 |
|
|
2019
Q4 | $7.15M | Buy |
114,790
+82,553
| +256% | +$3.93M | ﹤0.01% | 2683 |
|
|
2019
Q3 | $1.21M | Buy |
32,237
+26,412
| +453% | +$1.15M | ﹤0.01% | 3904 |
|
|
2019
Q2 | $237K | Buy |
+5,825
| New | +$208K | ﹤0.01% | 4713 |
|
Goldman Sachs's TPTX Position: Q3 2022 in Review
Goldman Sachs sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 913,245 shares — an estimated $68.7M sold.
Goldman Sachs first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $68.7M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Goldman Sachs reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Goldman Sachs sold 913,245 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $68.7M.
- Goldman Sachs first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Goldman Sachs's Turning Point Therapeutics, Inc. Common Stock position peaked at $68.7M in Q2 2022.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.